Natco Pharma: A Long-Term Investor's Honest Assessment at ₹883
A deep-dive analysis of Natco Pharma using all 12 pharma-specific metrics — revenue mix, FDA compliance, Para IV pipeline, return ratios, and valuation — at a time when the stock sits 28% off its 52-week high.
